This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Allergan plc

Drug Names(s): DA-8159, WC3043 (for ED), Zydena (Korea), WC3055 (for BPH), Udzire (India), ME3113

Description: Udenafil is an oral, PDE-V inhibitor. It has a Tmax of 1-1.5 hours and a half-life of 11 to 13 hours, that should be long enough for efficacy to last up to 24 hours.

Deal Structure: Dong-A PharmTech plans to oversee non-Korean development programs for udenafil. Dong-A PharmTech is an affiliate of Dong-A Pharmaceutical.

In April 2013, the Company changed its name from Dong-A Pharmtech Co., Ltd. to Mezzion Pharma Co., Ltd.

Dong-A and Dr. Falk Pharma
In 2006, Dong-A entered into an agreement with Dr. Falk Pharma for the development of udenafil in Europe.

Dong-A and Warner Chilcott
In January 2009, Warner Chilcott announced that it has signed an agreement with Dong-A PharmTech to develop and market udenafil for the treatment of erectile dysfunction (ED) in the United States. Under the terms of the agreement, Warner Chilcott has exclusive U.S. rights to develop and market the product for the treatment of ED. Dong-A will receive an initial, up-front payment and may also be eligible to receive additional payments upon achievement of certain milestones.

In April 2010, Warner Chilcott amended its agreement with Dong-A to...See full deal structure in Biomedtracker

Partners: Dong-A Socio Holdings Co., Ltd Dr. Falk Pharma GmbH Zydus Cadila Meiji Seika Pharma Co., Ltd

Udenafil News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug